Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer

A 56-year old woman with BRCA-associated breast cancer and recurrent ovarian cancer was treated with a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, rucaparib, in the setting of dialysis-dependence which required dose modification. Rucaparib trough levels were obtained before and after dialy...

Full description

Saved in:
Bibliographic Details
Published inGynecologic oncology reports Vol. 26; pp. 91 - 93
Main Authors Harold, Justin A., Free, Stephanie C., Bradley, William H.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Inc 01.11.2018
Elsevier
Subjects
Case Report
Online AccessGet full text

Cover

More Information
Summary:A 56-year old woman with BRCA-associated breast cancer and recurrent ovarian cancer was treated with a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, rucaparib, in the setting of dialysis-dependence which required dose modification. Rucaparib trough levels were obtained before and after dialysis and a clinically significant disease response was appreciated. •PARPi can be used safely in a dialysis dependent BRCA mutated patient with breast and ovarian cancer.•PK levels below those described in clinical trials are associated with clinical benefit.•Toxicities seen are similar to those in subjects with normal GFR.
ISSN:2352-5789
2352-5789
DOI:10.1016/j.gore.2018.10.011